{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-090821","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.516700+00:00","generated_at":"2026-06-04T00:59:13.140044+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Enliven Therapeutics appoints Dr. Lori Kunkel to Board of Directors","bullets":["Dr. Kunkel appointed as Class III director, term expiring at 2026 annual meeting.","Annual cash retainer of $35,000; stock option grant with fair value ~$500,000 vesting monthly over 3 years.","No arrangements or transactions requiring disclosure under Item 404(a) of Reg S-K.","Dr. Kunkel brings 25+ years oncology drug development experience; previously scientific advisor to Enliven."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-090821","json":"https://secwatch.observer/filing/0001193125-24-090821.json","markdown":"https://secwatch.observer/filing/0001193125-24-090821.md","text":"https://secwatch.observer/filing/0001193125-24-090821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312524090821/0001193125-24-090821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312524090821/d816494d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:59:13.140044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9d9a78d08","claim":"Lori Kunkel was appointed as Class III Director at Enliven Therapeutics, Inc..","evidence_excerpt":"On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312524090821/0001193125-24-090821-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}